Boehringer Ingelheim with an investment of US$314 million (EUR 285 million) plans to build a new Chemical Innovation Plant in Ingelheim, Germany.
The Chemical Innovation Plant will be a multi-floor building spanning 11,500 square meters. It will house four production lines along with dedicated development areas.
The new plant will focus on developing manufacturing processes for active pharmaceutical ingredients and producing drugs for use in clinical trial phases. This investment aims to offer life-saving and more effective therapy options to patients.
This facility is a significant step towards expanding its manufacturing capabilities and securing its long-term capacity for producing new chemical entities.
The facility has been designed to accommodate future expansions and incorporate new technologies, ensuring adaptability to evolving needs.
The construction of the new Chemical Innovation Plant, strengthens the long-term manufacturing capacity for new chemical entitie.
The new facility is expected to be operational from 2026.
Type New Construction
Budget US$314 million (EUR 285 million)